FTC would ‘eviscerate’ attorney-client privilege, says Boehringer
01-06-2017
Mari / iStockphoto.com
The US Chamber of Commerce and the Association of Corporate Counsel (ACC) have filed an amicus curiae brief in support of Boehringer Ingelheim Pharmaceuticals in its dispute with the Federal Trade Commission (FTC).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
US Chamber of Commerce, the Association of Corporate Counsel, FTC, Boehringer Ingelheim, Barr Pharmaceuticals, pay-for-delay, competition, patent,
